See more : UpHealth, Inc. (UPH) Income Statement Analysis – Financial Results
Complete financial analysis of Sigilon Therapeutics, Inc. (SGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigilon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nevro Corp. (NVRO) Income Statement Analysis – Financial Results
- United Health Products, Inc. (UEEC) Income Statement Analysis – Financial Results
- AOKI Holdings Inc. (8214.T) Income Statement Analysis – Financial Results
- Hung Ching Development & Construction Co., Ltd. (2527.TW) Income Statement Analysis – Financial Results
- Corporativo GBM, S.A.B. de C.V. (GBMO.MX) Income Statement Analysis – Financial Results
Sigilon Therapeutics, Inc. (SGTX)
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 37.63M | 65.07M | 53.49M | 48.11M | 21.04M |
| General & Administrative | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Other Expenses | 1.45M | 55.00K | -89.00K | -6.00K | -81.00K |
| Operating Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Cost & Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Interest Income | 946.00K | 258.00K | 312.00K | 1.06M | 698.00K |
| Interest Expense | 2.29M | 1.99M | 1.20M | 650.00K | 289.00K |
| Depreciation & Amortization | 2.40M | 313.00K | 223.00K | 1.73M | 374.00K |
| EBITDA | -41.27M | -75.32M | -52.42M | -42.40M | -22.08M |
| EBITDA Ratio | -318.84% | -784.70% | -391.95% | -299.51% | -476.26% |
| Operating Income | -43.67M | -75.64M | -52.64M | -44.12M | -23.08M |
| Operating Income Ratio | -337.35% | -787.96% | -393.61% | -311.71% | -497.63% |
| Total Other Income/Expenses | 105.00K | -1.68M | -1.97M | 198.00K | 310.00K |
| Income Before Tax | -43.56M | -77.31M | -54.61M | -43.93M | -22.77M |
| Income Before Tax Ratio | -336.53% | -805.41% | -408.31% | -310.31% | -490.94% |
| Income Tax Expense | -105.00K | 925.00K | 259.00K | 644.00K | 599.00K |
| Net Income | -43.46M | -78.24M | -54.87M | -44.57M | -22.77M |
| Net Income Ratio | -335.72% | -815.04% | -410.25% | -314.86% | -490.94% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| Weighted Avg Shares Out | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
| Weighted Avg Shares Out (Dil) | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
Here's Why Sigilon Therapeutics Stock Is Tanking Today
Why Galectin Is Soaring And Sigilon Is Sinking Today
Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop
Sigilon Therapeutics Stock Falls Over 20% Pre-Market: Why It Happened
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A
Biotech Losers In 2021 That Could Bounce Big In The Second Half
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors
Source: https://incomestatements.info
Category: Stock Reports